RAPT

In a report released today, Mike Kratky from SVB Securities maintained a Buy rating on RAPT Therapeutics (RAPT - Research Report), with a price target of $48.00. The company's shares closed today at $24.36.According to TipRanks, Kratky is a 3-star analyst with an average return of 17.5% and a 100.00% success rate. Kratky covers the Healthcare sector, focusing on stocks such as Morphic Holding, Pliant Therapeutics, and Kymera Therapeutics.Currently, the analyst consensus on RAPT Therapeutics is a Strong Buy with an average price target of $43.00.
https://www.tipranks.com/news/blurbs/rapt-therapeutics-rapt-receives-a-buy-from-svb-securities?utm_source=advfn.com&utm_medium=referral